Intec Pharma Begins Clinical Trials For Ulcer Treatment

December 10, 2015 | Jerusalem based clinical-stage biopharmaceutical company Intec Pharma announced that it is entering a Phase I clinical trial with its third pipeline product. The treatment is based on its Accordion Pill platform technology which opens in the stomach just before reaching the intestine and releases drugs slowly at the desired absorption point. The current line of drugs is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug (NSAID) induced ulcers. Led by CEO Zeev Weiss, the company raised $27 million in its Nasdaq IPO this year after the FDA approved its filing for Phase III trials for another pipeline drug designed to treat Parkinson’s disease.